Treatment goals in Crohn's disease (CD) are evolving beyond the control of symptoms towards deep remission, which encompasses clinical remission and mucosal healing. The ultimate goals are to prevent bowel damage, reduce long-term disability, and maintain normal quality of life. Until recently, goals of CD management focused on induction and maintenance of a symptomatic response, and little attention was paid to the delay or even prevention of disease progression. A very different approach is taken with other chronic diseases, such as hypertension, diabetes, and rheumatoid arthritis. This more comprehensive approach is often referred to as ‘treat-to-target' strategy. The treat-to-target strategy defines a new treatment objective that aims to achieve and sustain both clinical remission and control of inflammation. With our new understanding of the etiopathophysiology of inflammatory bowel disease, are we mistreating our patients? The most convincing concept at this time is that of a defective mucosal barrier due to inappropriate recognition of the luminal flora or a defective defense against those bacteria. These recent theories indicate that the paradigm of immune suppression may not be the optimal concept. Therefore, a variety of approaches to improve the barrier function or to modulate luminal components have to be considered. We still have much to learn about these concepts in order to achieve the treatment goals of avoiding structural damage and complications.

Keywords:
Crohn’s disease, Inflammatory bowel disease, Top-down therapy, Treat-to-target strategy
1.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-1794.
2.
Burisch J, Munkholm P: Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol 2013;29:357-362.
3.
Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-241.
4.
Hanauer SB, Kirsner JB: Treat the patient or treat the disease? Dig Dis 2012;30:400-403.
5.
Markowitz J, Grancher K, Kohn N, Lesser M, Daum F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
6.
Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ: Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis 2012;6(suppl 2):S224-S234.
7.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, DʼHaens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-1395.
8.
Walters TD, Kim MO, Denson LA, et al: Increased effectiveness of early therapy with anti-tumor necrosis factor alpha vs an immunomodulator in children with Crohn's disease. Gastro 2014;146:383-391.
9.
Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ: Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-1201.
10.
Khor B, Gardet A, Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317.
11.
Fiocchi C: Genes and ‘in-vironment': how will our concepts on the pathophysiology of inflammatory bowel disease develop in the future? Dig Dis 2012;30(suppl 3):2-11.
12.
Peterson DA, Frank DN, Pace NR, Gordon JI: Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008;3:417-427.
13.
Hviid A, Svanstrom H, Frisch M: Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011;60:49-54.
14.
Albenberg LG, Lewis JD, Wu GD: Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol 2012;28:314-320.
15.
De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P: Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010;107:14691-14696.
16.
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S: Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-753.
17.
Gupta K, Noble A, Kachelries KE, Albenberg L, Kelsen JR, Grossman AB, Baldassano RN: A novel enteral nutrition protocol for the treatment of pediatric Crohn's disease. Inflamm Bowel Dis 2013;19:1374-1378.
18.
Scholmerich J: Evolving concepts in IBD therapy: what should be studied in the future? Dig Dis 2010;28:472-477.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.